

IN-SILICO AND IN-VITRO APPROACHES TO SCREEN THE ANTI-TUBERCULOSIS ACTIVITY OF BENZOTHAIAZOLE ANALOGS

Editors:

Mahesh Bhat
S.L. Belagali

Bentham Books

In-Silico and In-Vitro
Approaches to Screen the Anti-
tuberculosis Activity of
Benzothiazole Analogs

Edited by

Mahesh Bhat

*PG Department of Chemistry,
JSS College for Women,
Saraswathipuram, Mysore-09,
Karnataka,
India*

&

S. L. Belagali (Rtd)

*Environmental Chemistry Laboratory,
DOS in Environmental Science,
University of Mysore, Mysore-06,
Karnataka,
India*

In-Silico and In-Vitro Approaches to Screen the Anti-tuberculosis Activity of Benzothiazole Analogs

Editors: Mahesh Bhat and S. L. Belagali

ISBN (Online): 978-981-14-9463-5

ISBN (Print): 978-981-14-9461-1

ISBN (Paperback): 978-981-14-9462-8

© 2021, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

FOREWORD	i
PREFACE	ii
LIST OF CONTRIBUTORS	iv
CHAPTER 1 INTRODUCTION TO BENZOTHAIAZOLE AS A DRUG MOIETY	1
<i>Mahesh Bhat, S.L. Belagali, B. Manohara and B.K. Sagar</i>	
1. INTRODUCTION	2
1.1. Introduction to Benzothiazole	2
1.2. Biology of the Benzothiazole	3
1.3. Chemistry of Benzothiazoles	5
1.3.1. Condensation of <i>o</i> -aminothiophenol with Acids	5
1.3.2. Synthesis of 2-aminobenzothiazole	6
1.4. Anti-TB Activity of Benzothiazole Derivatives	9
CONCLUSION	15
CONSENT FOR PUBLICATION	15
CONFLICT OF INTEREST	15
ACKNOWLEDGEMENTS	15
REFERENCES	15
CHAPTER 2 STRUCTURAL ACTIVITY RELATIONSHIP AND <i>IN-SILICO</i> METHODS IN DRUG DESIGN	19
<i>Mahesh Bhat, S.L. Belagali and E.V. Sekhar</i>	
1. STRUCTURAL ACTIVITY RELATIONSHIP	19
1.1. Substituent Modification	20
1.1.1. Source of SAR	21
1.1.2. Evolution of QSAR	21
1.1.3. Challenging in QSAR Model	24
1.1.4. Reliability of the Method	26
1.2. <i>In-Silico</i> Methods in Drug Design	28
1.2.1. Why Molecular Docking Required	28
1.2.2. Molecular Docking Approach	30
1.2.3. Drug-DNA Interaction	31
1.2.4. Different Types of Interaction	31
1.2.5. Types of Docking	32
1.2.6. Basic Requirements for Molecular Docking	32
1.3. Structural Data	32
1.3.1. Ligand Representation	32
1.3.2. Receptor Representation	33
1.3.3. Receptor Flexibility	33
1.4. Major Steps in Carry Out the Molecular Docking	36
1.4.1. Step I – Building the Receptor	36
1.4.2. Step II-Identification of the Active Site	36
1.4.3. Step III-Ligand Preparation	36
1.4.4. Step IV- Docking	37
1.5. Applications of Molecular Docking	37
1.6. Adopted Methodology	38
CONSENT FOR PUBLICATION	39
CONFLICT OF INTEREST	39
ACKNOWLEDGEMENTS	39

REFERENCES	39
CHAPTER 3 MYCOBACTERIUM TUBERCULOSIS AND IN-VITRO METHODS FOR SCREENING ANTI-TB DRUGS	44
<i>Mahesh Bhat, S.L. Belagali, B. Manohara and S.V. Mamatha</i>	
1. MYCOBACTERIUM TUBERCULOSIS	44
2. EVOLUTION OF THE TUBERCULOSIS DRUG	47
3. ANTI-TB ACTIVITY	54
3.1. Alamar Blue Assay	54
3.1.1. Materials Required	54
3.1.2. Working Procedure	55
3.2. MGIT 960 Assay of M. Tuberculosis	55
3.2.1. Materials Required	55
3.3. PZase Inhibitory Activity Assay	56
3.3.1. Materials Required	56
3.4. REMA Plate Method	56
3.4.1. Materials Required	56
3.5. The MTT Assay	57
3.5.1. Materials Required	57
3.6. Nitrate Reductase Assay/Greiss Method	58
3.6.1. Materials Required	58
3.7. Mycobacterial Growth Inhibition Assay (MGIA) for Bovine TB	58
3.8. Microscopically Observed Drug Susceptibility Assay (MODS)	59
3.8.1. Working Procedure	59
3.9. Flow Cytometry Method	60
3.10. Radiometric Assay for <i>M. aurum</i>	60
3.11. <i>In-Vivo</i> Florescence Imaging Method	60
3.12. <i>In-Vivo</i> Treatment of <i>M. Bovis</i>	61
CONSENT FOR PUBLICATION	62
CONFLICT OF INTEREST	62
ACKNOWLEDGEMENTS	62
REFERENCES	62
CHAPTER 4 SYNTHESIS AND ANTI-TB ACTIVITY SCREENING OF BENZOTHIAZOLE AMIDE DERIVATIVES	66
<i>Mahesh Bhat and S.L. Belagali</i>	
1. INTRODUCTION	66
2. SYNTHESIS OF BENZOTHIAZOLE AMIDE DERIVATIVES	68
2.1. Chemistry	68
2.2. Synthesis of 2-[(tert-Butoxy Carbonyl) Amino]-3-(4-nitro Phenyl) Propanoic Acid	69
2.3. General Procedure for the Synthesis of Amide Derivatives	69
2.4. General Procedure for BOC Group Deprotection	70
2.5. Synthesis of Ethyl Benzothiazole-2-carboxylate	70
2.6. Mechanism of Acid Amine Coupling by T3P	71
2.7. Synthesis of Benzothiazole-2-carboxylic Acid	71
2.8. Synthesis of Benzothiazole Amide Derivatives	71
3. MECHANISM OF ACID AMINE COUPLING BY HATU	72
4. ANTI-TB ACTIVITY	73
CONCLUSION	74
CONSENT FOR PUBLICATION	74
CONFLICT OF INTEREST	75
ACKNOWLEDGEMENTS	75

REFERENCES	75
CHAPTER 5 SYNTHESIS AND ANTI-TB ACTIVITY STUDIES OF BENZOTHAZOLE GUANIDINYL DERIVATIVES	77
<i>Mahesh Bhat and S.L. Belagali</i>	
1. INTRODUCTION	77
2. EXPERIMENTAL SECTION	80
2.1. Synthesis of Benzothiazole Thiourea Derivatives	80
2.2. Synthesis of Benzothiazole Guanidiny Derivatives	81
2.3. Mechanism	82
3. RESULTS AND DISCUSSION	83
3.1. Chemistry	83
3.2. Anti-TB Activity	83
4. MOLECULAR DOCKING STUDIES	84
CONCLUSION	87
CONSENT FOR PUBLICATION	88
CONFLICT OF INTEREST	88
ACKNOWLEDGEMENTS	88
REFERENCES	88
CHAPTER 6 SYNTHESIS AND ANTI-TB ACTIVITY SCREENING OF PYRAZOLE CONJUGATED BENZOTHAZOLE ANALOGS	90
<i>Mahesh Bhat and S.L. Belagali</i>	
1. INTRODUCTION	90
2. EXPERIMENTAL SECTION	93
2.1. Materials and Methods	93
3. SYNTHESIS OF PYRAZOLE CONJUGATED BENZOTHAZOLE DERIVATIVES	93
3.1. Synthesis of 2-amino Benzothiazole	93
3.2. Synthesis of Benzothiazole-2-hydrazine	94
3.3. General Procedure for the Synthesis of 1-phenyl-2-(1-phenyl Ethylidene) Hydrazine ...	94
3.4. Synthesis of Pyrazole Derivatives	95
3.5. General Procedure for the Synthesis of Pyrazole Conjugated Benzothiazole Derivatives	95
3.6. Synthesis of Benzothiazole-2- ethyl Carboxylate	96
3.7. Synthesis of 1, 3-benzothiazole-2-carbohydrazide	97
3.8. General Procedure for the Synthesis of Pyrazole Conjugated Benzothiazole Derivatives	97
4. MECHANISM	97
5. RESULTS AND DISCUSSION	100
5.1. Chemistry	100
5.2. Anti-TB Activity	100
CONCLUSION	105
CONSENT FOR PUBLICATION	106
CONFLICT OF INTEREST	106
ACKNOWLEDGEMENTS	106
REFERENCES	106
SUBJECT INDEX	108

FOREWORD

Tuberculosis is a serious infectious disease, which is caused by the *Mycobacterium tuberculosis*, generally it affects the lungs. Tuberculosis is spread from one person to another through microscopic droplets released into the air, it can happen through coughs, speaks, sneezes, spits, laughs from the active tuberculosis patient. According to the recent survey on tuberculosis by world Health Organization, in 2018, 10 million people fell ill with TB, and 1.5 million died from the disease. These numbers are alarming the need for more efforts to fight against the tuberculosis.

The book entitled “*In-Silico* and *In-Vitro* Approaches to Screen the Anti-tuberculosis Activity of Benzothiazole Analogs” comprises of six chapters, with extensive literature documentation on the benzothiazole analogs and corresponding structure activity relations, further authors enumerated the *in-vitro* and *in-silico* methodology for the screening the benzothiazole molecules to the anti-TB regime. Further various chapters explained the synthesis of the different types of the benzothiazole scaffold moiety and their tuberculosis activities with neat descriptions of the methodology. Additionally, each chapter includes the synthetic schemes, with mechanism for the benzothiazole derivatives.

I am happy to recommend this book to students and researchers of the Universities and research centers as a reference book. This book is written in the way that it is student friendly with the help of the diagrams, tables, reaction schemes and mechanisms. This book helps to get the glimpse on tuberculosis diseases and the wide information to carry out further research on the benzothiazole. I sincerely believe that, this book has been prepared with scientific skills and experimental details and will serve as a useful document for the researchers.

B. Shivarama Holla
Professor of Chemistry
SDM College (autonomous)
Ujire, Dakshina Kannada
574240, India

PREFACE

Tuberculosis (TB) continues to have a remarkable impact on human healthcare worldwide, even though availability of anti-tubercular treatment (ATT) from the last five decades. The worldwide statistical data on tuberculosis was surprised to know that, nearly one-third of the world population is infected with tuberculosis and newly 1% of the population of each year adds to this number and also causes about 1.7 million deaths every year. Tuberculosis is an infectious disease spread by the *Mycobacterium tuberculosis*, a small, aerobic, nonmotile *bacillus*, which divides every 16 to 20 hours, it is a extremely slow rate compared with the other bacteria. Whatever drugs used for the treatment of tuberculosis diseases were developed in the mid of last century. There is need of more advanced treatment of TB because changes in the environmental conditions, genetic modification in human beings and also in tuberculosis species which influences the medication procedure and also treat the multi drug resistance bacteria.

In the earlier days, natural substances were used for their nutritional value and also for the treatment of diseases. We can use the traditional medicines to cure the various diseases, but it has some limitations *viz*, purification difficulties from the raw source, difficult to get in large quantity *etc*. From the 19th century, new methods were used for the treatment of diseases with synthetic drugs, modification of the natural products through the synthetic process adopted for the synthesis of useful semi synthetic drugs. The improvement in the life style has been greatly influenced by the advancement in the field of medicinal chemistry, the useful applications of life surviving medicines makes much advanced inventions in the field of synthetic chemistry.

Now-a-days computer aided applications *i.e. in-silico* tool is the modern trend of application in the drug designing investigations, which gives the idea regarding how synthetic compound interact with particular protein and mechanism of action. *In-silico* tool is also helpful to relate the structure and activity of particular series of the organic molecules. To know the molecular interaction with protein, here discussed the molecular docking study enoyl acyl carrier reductase (InhA) of *M. tuberculosis* (PDB ID: 1ZID) and decaprenyl phosphoryl-D-ribose oxidase (DprE1), (PDB ID: 4FDO).

In this book we have made an attempt to search the alternate drug molecule for the substituent. Here we have taken the benzothiazole moiety and elucidate the Quantitative structural activity relationship, *in-silico* computer aided drug design for the tuberculosis and followed by the *in-vitro* methods for analysis. In the first chapter of the book we have briefly explained the importance of the benzothiazole moiety in the medicinal chemistry and corresponding QSAR study. Second chapter covers the structural activity relationship models, *in-silico* and *in-vitro* procedure for the tuberculosis drugs. In this section, briefly explained various concepts regarding tuberculosis, causes, symptoms and present treatment. In the later chapters covers the synthesis, anti-TB activity of the benzothiazole derivatives such as, benzothiazole diamide, benzothiazole guanidiny derivatives, benzothiazole conjugated pyrazole derivatives and benzothiazole azo-ester derivatives.

This hand book gives the information regarding TB diseases, methods of *in-silico* and *in-vitro* for anti-tuberculosis and importance of the benzothiazole in TB regime. Totally this book is suitable for, those who are interested in discovering the tuberculosis drug, researcher and post graduate students.

I am thankful to the efficient team of Bentham Science Publishers especially, Humaira

Hashmi, In-charge Book Department, Editorial Manager Publications and his team valuable suggestions during the construction of this book.

Mahesh Bhat
JSS College for Women
Mysore, India

List of Contributors

- S.L. Belagali** Environmental Chemistry Laboratory, DOS in Environmental Science, University of Mysore, Mysore-06, Karnataka, India
- Mahesh Bhat** Department of Chemistry, JSS College for Women, Saraswathipuram, Mysore-09, Karnataka, India
- S.V. Mamatha** Environmental Chemistry Laboratory, in Environmental Science, University of Mysore, Mysore-06, Karnataka, India
- B. Manohara** Department of Chemistry, Vivekananda College, Puttur-574 203, Karnataka, India
- B.K. Sagar** Department of Chemistry, MDRPU Science College, Varakodu, Mysore-570 010, Karnataka, India
- E.V. Sekhar** Department of Chemistry, JSS College for Women, Saraswathipuram, Mysore-09, Karnataka, India

CHAPTER 1**Introduction to Benzothiazole as a Drug Moiety****Mahesh Bhat^{1,*}, S.L. Belagali², B. Manohara³ and B.K. Sagar⁴**¹ Department of Chemistry, JSS College for Women, Saraswathipuram, Mysore-09, Karnataka, India² Environmental Chemistry Laboratory, DOS in Environmental Science, University of Mysore, Mysore-06, Karnataka, India³ Department of Chemistry, Vivekananda College, Puttur-574 203, Karnataka, India⁴ Department of Chemistry, MDRPU Science College, Varakodu, Mysore-570 010, Karnataka, India

Abstract: Benzothiazole (1, 3-benzothiazole) is one of the important fused heterocyclic compounds, which is a weak base having varied biological activities. The unique methyne center present in the thiazole ring makes benzothiazole as the most bioactive heterocyclic compound. The benzothiazole subunit is the commonly found in many natural bioactive compounds and semisynthetic drugs. Benzothiazole and its analogous found to exhibit variety of bio-activities, also with less toxic effect and their derivatives showed the enhanced activities, which has proven Benzothiazole scaffold is one of the prominent moiety in the medicinal chemistry, presence of hetero atoms such as sulphur and nitrogen makes the receptor cite in the parent moiety for the observed activity. Benzothiazole derivatives possess various pharmacological activities such as anti-viral, anti-microbial, anti-allergic, anti-diabetic, anti-tumor, anti-inflammatory, anthelmitic and anti-cancer activities. Which makes chemistry of benzothiazole is makes the prominent, rapidly developing and interesting field in the medicinal chemistry. In this chapter, briefly explained the importance, common methods of synthesis of the benzothiazole scaffold and also explained the popular benzothiazole molecules which have applications in various fields of the chemistry. Main objective of this chapter to explore various pharmacological activities containing benzothiazole moieties and rationalized the activities based on the structural variations with respect to the tuberculosis activity. The studies on benzothiazole derivatives reveal that, substitution on the C-2 and C-6 positions are the reasons for variety of biological activities.

Keywords: Activity, Benzothiazole, Cyclization, Docking, Docking score, DprE1, GuanidinyI, H37Rv Strain, Heterocycle, IC₅₀, InhA, Luciferin, MIC, MTT, Pyrazole, SAR, TB activity, Thiazole, Triazole, Tuberculosis.

* Corresponding author **Mahesh Bhat:** Department of Chemistry, JSS College for Women, Saraswathipuram, Mysore-09, Karnataka, India; Tel: +91 9538065170; E-mail: maheshbhat08@gmail.com

Mahesh Bhat & S.L. Belagali (Eds.)
All rights reserved-© 2021 Bentham Science Publishers

1. INTRODUCTION

The compound derived from the heterocyclic compounds have important role in the field of medicinal chemistry. The various activities and less toxicity to the normal cells makes these compounds are privileged structures in the medicinal chemistry. The presence of the hetero atom in the ring helps to make the interactions with DNA of various microorganisms. In pharmaceutical industries more than 75% of the top two hundred drugs contain heterocyclic units in their structure. In many of the heterocyclic compounds, benzene ring is fused with five membered hetero atom containing ring. These structures are the more consideration by the researcher because of the enhanced activity towards the various microorganisms [1]. In indole six membered rings fused with pyrrole moiety, where as in benzothiazole six membered benzene ring fused with thiazole moiety, some of such structures are shown in Fig. (1).




Fig. (1). Fused heterocyclic compounds.

1.1. Introduction to Benzothiazole

Benzothiazole is a class of fused heterocyclic compound, it is formed by the fusion of benzene ring with five membered thiazole ring at 1 and 4th position. The resultant compound is planar and the various positions of the atoms are numbered in such a way that, sulfur atom is numbered 1, followed by methylene carbon atom and then nitrogen of the ring as represented in Fig. (2). The benzothiazole compound is neutral exist in liquid form and insoluble in the aqueous solutions. Benzothiazole exists in all eukaryotes, ranging from yeast to humans. Naturally benzothiazole found in various food and beverages such as safflower, guava, potato, and fruits *etc.* Benzothiazole has the major role in plant metabolite, a xenobiotic and an environmental contaminant.




Fig. (2). Numbering of atoms in benzothiazole.

The unique methyne center present in the thiazole ring makes benzothiazole as the most important heterocyclic compound and some of the compounds containing benzothiazoles are also found in nature. This electron-withdrawing moiety is thermally stable with diversified applications in various fields of chemistry, such as thioflavin used as a coloring agent and some benzothiazole moieties are used as drugs in pharmaceuticals, for example Riluzole. During the vulcanization of rubber, 2-mercaptobenzothiazole has been used as the accelerator and the ring is a potential component in nonlinear optics (NLO). The presence of the sulfur and nitrogen hetero-atoms in thiazole unit of Benzothiazole makes molecules is capable of binding with multiple receptors with high affinity [2, 3]. These types of the nitrogen and sulfur containing heterocycles play important roles in not only life science but also in other industrial sector related to speciality and fine chemicals.

1.2. Biology of the Benzothiazole

The benzothiazole chemistry begins with the synthesis of 2-Mercapto-benzothiazole by A. W. Hofmann an accidental invention. The chemistry of benzothiazole was accelerated in the mid of 20th century. The various important benzothiazole moieties are found in the different fields of medicines and biological sciences. Table 1 indicates the prominent moieties in the different fields.

Benzothiazole derivatives are used in all the branches of chemistry, in polymer chemistry it catalyses the formation of sulfide linkage between the unsaturated elastomeric polymers, the obtained polymer was more flexible and larger cross-linked material, as compared to the synthesized by other conventional methods [5].

CHAPTER 2

Structural Activity Relationship and *In-Silico* Methods in Drug Design

Mahesh Bhat^{1,*}, S.L. Belagali² and E.V. Sekhar¹

¹ Department of Chemistry, JSS College for Women, Saraswathipuram, Mysore-09, Karnataka, India

² Environmental Chemistry Laboratory, DOS in Environmental Science, University of Mysore, Mysore-06, Karnataka, India

Abstract: Bioactivity of the synthesized compounds depends upon the molecular morphology of the compounds. The presence of the number of heteroatoms and ring size and shape of the molecules influences the corresponding biological activity. To predict the biological activity, structural activity relationship is one of the traditional non-computational method and from this methods, activity relation with structure can correlate. In this chapter discussed the source of the SAR, reliability of the method and general information. To predict the activity of the molecule, various computational methods were also developed, this method is called *in-silico* method. In continuation of this chapter, molecular docking, source of molecular docking, different types of docking, various interactions, docking process and applications are discussed.

Keywords: Algorithm, Benzothiazole, Binding sites, Docking, DprE1, Drug design, Dynamics, HTS, InhA, *In-silico*, *In-vitro*, Ligand, MTT assay, Nitroimidazole, Pyrrole, PZase, QSAR model, Receptor, Rigidification, SAR, Tuberculosis.

1. STRUCTURAL ACTIVITY RELATIONSHIP

Structure Activity Relationships (SAR) is the traditional non-computational method and can be used to predict biological activity from two dimensional molecular structures. It is the collection of the molecules and their associated activities. Synthesis of new target oriented compounds for various diseases helpful to do required modification in the existing molecule.

The biological characteristics of the new designed compound can be predicted from comparing the molecular structure of the designed compound with the simi-

* Corresponding author Mahesh Bhat: Department of Chemistry, JSS College for Women, Saraswathipuram, Mysore-09, Karnataka, India; Tel: +91 9538065170; E-mail: maheshbhat08@gmail.com


lar structure available in the literature. These are because the similar compounds have similar physical, chemical and biological properties. So there is a relationship between the molecular structure and their biological activity. The analysis of SAR gives the idea regarding determination of the group or atom, or functional group which is responsible for the evoking of targeting biological effect in the organism. This allows the modification of the effect or potency of bioactive compounds by changing its chemical structures. Qualitative predictions are based on the comparison of the valid measured data from the literature from one or more analogue with the chemical structure of interest. The level of the toxicity like, less toxic, moderate toxic and more toxic used to qualitatively can be assumed from this method. Qualitative and quantitative predictions are usually in the form of a regression equation and it gives the predicted dose response data. CDD vault (Collaborative Drug Discovery Inc.) is the SAR tool, detects the correlation and builds the model used for the evaluation of the chemical structure to predict the biological activity.

The activity of the benzothiazole and their structural diversity can be correlated with each other. The enhancement of the biological activity in the series of the derivatives mainly depends on the substituent present in the molecule. Electron donating, electron withdrawing, hydrophilic and hydrophobic groups influence the activity of the synthesized compounds along with core moiety. Structure Activity Relationship (SAR) is the study of the relationships between a drug's molecular structure and the drug's biological activity. Structure activity relationship studies are significant for designing a pharmaceutical drug with the greatest potential activity and least side effects.

The relationship between the structure of the chemical species and pharmacological activity for a series of compounds depends on their structural characteristics in common, including shape, size, stereo-chemical arrangement and distribution of functional groups. Some other factors contributing to structure activity relationship include electronic effects, chemical reactivity, resonance and inductive effects.

1.1. Substituent Modification

Consider the two identical structures of the adrenaline and isoprenaline, isoprenaline is the *N*-isopropyl derivatives of the adrenaline. Isoprenaline has the greater selectivity β adrenoreceptor agonist compare to the adrenaline. Isoprenaline is also used for the treatment of brandycardia, heart block and rarely for asthma. By changing the isopropyl group instead of the methyl enhances the activity, this indicates the *N*-substitution enhances the activity.



Structural Simplification: SAR technique allows the structural simplification by knowing which part of the moiety is responsible for the activity and unwanted part of the structure. For an example in many cases the auxochrome is not responsible for the bioactivity, which can be omitted from the structure without affecting the activity.

Rigidification: For better biological activity, particular stereo specific conformation is also important. Molecules have different biological activity in different conformations. Rigidification restrict the conformational, so the rigidness of the molecule is also important.

1.1.1. Source of SAR

The source of the SAR data can be sub divided into two categories, one is those based on the statistical data (*e.g.* regression models) and another one is based on the physical approaches (*e.g.*, pharmacophore models). Depending upon what extent and how much details are explored on the SAR model which influences the selecting model for carry out the SAR Study. SAR statistical data of two dimensional descriptor ignores stereochemistry. Chiral carbon exhibits the stereochemistry, which exhibit the different conformations and influences the activity. So three dimensional approaches are generally more informative, that gives the information regarding the ligand-receptor interactions with particularly stereo-chemical conformational information. In most of the biological system it is unreasonable to expect linear relationships because the *in-vivo* activity is the complex and multiple process. In all, the method depends on the analysis of the set of the previous reported molecules. From the SAR one can build the model as a predictive method. Such virtual screening can apply the designed molecule and can obtain the numerical prediction of the activity. Key to such an exploration depends upon understanding the ability of how exactly the structure of molecules is correlated with observed activity to specific structural species [1, 2].

1.1.2. Evolution of QSAR

Modern QSAR practices are based on the publication of the Hansch *et al.*, in

Mycobacterium Tuberculosis and In-Vitro Methods for Screening Anti-TB Drugs

Mahesh Bhat^{1,*}, S.L. Belagali², B. Manohara³ and S.V. Mamatha²

¹ Department of Chemistry, JSS College for Women, Saraswathipuram, Mysore-09, Karnataka, India

² Environmental Chemistry Laboratory, DOS in Environmental Science, University of Mysore, Mysore-06, Karnataka, India

³ Department of Chemistry, Vivekananda College, Puttur-574 201, Karnataka, India

Abstract: Tuberculosis is a most infectious dangerous health problems caused by the *Mycobacterium tuberculosis*, the species mainly affects the lungs, it can also spreads to various parts of the body like the brain and the spine and second biggest killer in the world. In this chapter, we have discussed about the *Mycobacterium tuberculosis* and its various types and symptoms of the tuberculosis diseases. Detailed history of the evolution of the tuberculosis treatment has been discussed, followed by the prominent drug molecules and their classification. To screen the molecules to tuberculosis, different methodologies are required; here various *in-vitro* and *in-vivo* methods have been discussed in-order to evaluate the drug capacity against the tuberculosis.

Keywords: Alamar Blue assay, Benzothiazole, Dubos broth Pyrazinamide, *in-vitro*, *in-vivo*, H37Rv strain, Ligand, LJ media, McFarland, MDRX, MTT assay, Nitroimidazole, Pyrazinamide, Pyrrole, PZase, Resazurin, Rifampicin, Streptomycin, Tuberculosis.

1. MYCOBACTERIUM TUBERCULOSIS

The improved pervasiveness of irresistible sicknesses undermines total population. Tuberculosis (TB) keeps on remarkably affecting human medicinal services around the world, despite the fact that accessibility of Anti-tubercular treatment (ATT) from the last 50 years. The worldwide statistical data on tuberculosis was surprised to know that almost 33% of the total population is tainted with tuberculosis and in recent year increase of 1% of the number of inha-

* Corresponding author Mahesh Bhat: Post Graduate Department of Chemistry, JSS College for Women, Saraswathipuram, Mysore-09, Karnataka, India; Tel: +91 9538065170; E-mail: maheshbhat08@gmail.com

bitants in every year [1] and furthermore causes around 1.7 million deaths consistently [2].

TB is an most dangerous health issue, spread by the *Mycobacterium tuberculosis*, (*Mycobacterium bovis* and *Mycobacterium africanum* are belongs to the same family and can causes tuberculosis) a small, aerobic, nonmotile *bacillus*, which undergo doubling every 16 to 20 hours, compare to other bacteria, this is the extremely slow rate of multiplication. In nature *Mycobacterium tuberculosis* grows only inside of the cells of the host organism. *Mycobacterium tuberculosis* mainly affects the lungs, it can also spreads various other part of the body like the brain and the spine and second biggest killer in the world. The statistical graphical representations are shown in Fig. (1).




Fig. (1). World wide tuberculosis deaths per million person in 2012. Courtesy: WHO 2009 report.

The microorganisms that cause tuberculosis are mycobacterium that has a common group that belongs is called *M. tuberculosis* complex. This complex involves the accompanying species:

- i. *M. tuberculosis*
- ii. *M. bovis* (subsp. *bovis* and *caprae*)

- iii. vaccine strain *M. bovis* BCG (*Bacille Calmette-Guérin*)
- iv. *M. africanum*
- v. *M. canettii*
- vi. *M. microti*
- vii. *M. pinnipedii*

Feeling debilitated or powerless, loss of craving and weight reduction, chills, fever, and night sweats, chest pain *etc.* are some of the symptoms of the tuberculosis diseases. TB spreads through air when a person with TB, sneezes, spits, laughs, or talks. Despite the fact that tuberculosis is a repairable illness, it is critical to grow new multi-target arranged medication compounds with lower poisonous in nature and lesser measurement. The absence of productive enemy of *Mycobacterium* operators against *Mycobacterium tuberculosis* is made to grow new multi-safe medication drug molecules.

Regimes for the treatment of tuberculosis diseases must contain multiple drugs to which bacteria are sensitive. Treatment with a single drug which can lead to the development of bacterial resistant to that drug. Tuberculosis is the major threat to the HIV infected people and it leads to death, it was estimated that, quarter million deaths occur in this group [3]. In 2013, over nine million new tuberculosis infected patients, 4,80,000 people being affected by the multi-drug resistant (MDR) *Mycobacterium tuberculosis* strains [4]. If the *Mycobacterium tuberculosis* strains show the *in-vitro* resistance to one of the standard drug like, isoniazid and rifampicin then it is called MDR strain, while extensively drug resistance (XDR-TB) is resistant to at least one of the fluoroquinolone and one injectable second line anti-TB drug along with isoniazid and rifampicin [5 - 7].

Majorly, this tuberculosis is affected in low income countries and pharmaceutical companies showed relatively less interest in developing new drugs for anti-TB diseases [8]. The clinical outcome of the MDR/X-DR-TB trials is largely sub-optimal and their treatment takes long time, toxic and expensive. These are serious difficulties to treat many TB disease cases, controlling and eliminating the disease [9]. A recent survey demonstrate that, in Germany MDR-TB related average costs exceeds the € 50,000 per patients, in Europe its more than € 1,60,000 [10], these study also reveals that, the success rate of TB treatment is only 54%. Every day this clinical trial faces the challenges, adverse effect, lack of clinical experiences, limited availability of adequate diagnostics, changing in lifestyle, changing in conditions and new problems in patient.

The World Health Organization recently started the innovative ‘End TB Strategy’ for supporting the TB elimination, with a vision that the world is free from TB, with zero deaths, suffering and diseases due to TB. The new policies of WHO

Synthesis and Anti-TB Activity Screening of Benzothiazole Amide Derivatives

Mahesh Bhat^{1,*} and S.L. Belagali²

¹ Department of Chemistry, JSS College for Women, Saraswathipuram, Mysore-09, Karnataka, India

² Environmental Chemistry Laboratory, DOS in Environmental Science, University of Mysore, Mysore-06, Karnataka, India

Abstract: Synthesis of diamide derivatives are carried out by the phenylalanine initially phenylalanine reacts with the aromatic amine by the acid amine coupling followed by de-protection of the boc and further reacts with the benzothiazole carboxylic acid by the formation of the amide coupling in the presence HATU as coupling reagent. Further series of the diamide benzothiazole derivative compounds were screened for the *in-silico* and *in-vitro* anti TB activity. In *in-silico* method compounds show a good docking score with respect to the standard drug. *In-vitro* Alamar blue assay demonstrate some of the compounds marked for the superior activity with minimum inhibitory concentration 1.6 µg/mL.

Keywords: Alamar Blue Assay, Amide, Anti-TB, Benzothiazole, Boc, Diethyl oxalate, DIPEA, Docking, DprE1, HATU, InhA, Isoniazid, MIC, Phenyl alanine, Pyrazinamide, T3P, Trifluoro acetic acid, Triethylamine, Tuberculosis.

1. INTRODUCTION

The amide functionality is wide spread in small or complex molecules of natural and synthetic compounds [1]. Amide functional group was found not only in enzymes, proteins, hemoglobin and immune protection antibodies but also is the basis for the versatile and widely used synthetic drugs and polymers [2]. In medicinal chemistry, more than 25% of compounds contain the carboxamide group and have high polarity, are neutral and stable, have conformational diversity and possess hydrogen bonding with accepting and donating properties, which makes them popular and reliable functional groups in synthetic organic chemistry [3].

* Corresponding author Mahesh Bhat: Department of Chemistry, JSS College for Women, Saraswathipuram, Mysore-09, Karnataka, India; Tel: +91 9538065170; E-mail: maheshbhat08@gmail.com

The functionality of amides are observed in different fields of chemistry such as, polymers (Nylon 6 6, urea formaldehyde polymer *etc.*), Pharmaceutical drugs (acetaminophen, phenacetin, empirin *etc.*), insecticides (carbaryl, isoprocarb *etc.*) and also as solvents, for example dimethyl formamide.

Paracetamol, lidocaine, cinchocaine, lipitor *etc.* are the amide containing drugs used for different medications. Paracetamol is used for pain and fever relieving; lidocaine ointment is used for different parts of the body to cause numbness and also used for pain relieving. Cinchocaine is used as spinal and topical anesthesia and also used in veterinary drugs, for example Somulose for horse and cattle. Lipitor reduces cholesterol levels and triglycerides in the blood. The marketed drugs of amide compounds are shown in Fig. (1).




Fig. (1). Marketed drugs containing amide functional groups.


Amides are one of the important building blocks of synthetic chemistry and exhibit numerous biological activities [4]. They have been reported for antibiotic [5], anti-malaria [6], anticancer [7] and antimicrobial activities [8]. So, amide bond transformation becomes the most executed transformation in organic chemistry. Many of the reported scientific investigations confirm that nitrogen and sulfur containing heterocyclic compounds are potential towards cancer, viral and fungal diseases. The bioactivity of the benzothiazole can be enhanced by constructing amide bonds with the 4-nitro phenylalanine amide derivatives. Benzothiazole is the fused heterocyclic compound containing nitrogen and sulfur hetero atoms in the ring and having the varied biological activities. The amino acids conjugated with heterocycles have proved enhanced activities [9, 10].

The uncontrolled proliferation of cells rather than normal cell behavior causes the starting of cancer. The substance which has ability to arrest the cell division is known as anti-mitotic drug. Many of the 2-substituted benzothiazoles are reported in literature for the moderate antimitotic activity [11]. So, in the present section, explained synthesis of phenylalanine conjugated benzothiazoles through the amide bond formation and evaluated for their anti-TB activities.

2. SYNTHESIS OF BENZOTHAZOLE AMIDE DERIVATIVES

2.1. Chemistry

The amino group of 4-nitro phenyl alanine was protected by the BOC-anhydride. T3P was used as the coupling reagent for the preparation of the amide derivatives of BOC protected 4-nitro phenylalanine and different aromatic amines. In the later step, the BOC protection was removed by Trifluoro acetic acid (TFA) to get a free amine group. The title compound was synthesized by the acid amine coupling of benzothiazole-2-carboxylic acid and 4-nitro phenylalanine amide derivatives with HATU as acid-amine coupling reagent as shown in Scheme 1.



Scheme 1. Synthesis of Benzothiazole amide derivatives. Reagents: **(a)** BOC anhydride, NaOH, *tert*- Butyl alcohol, **(b)** R_1NH_2 , T3P[®], TEA, EtOAc **(c)** TFA, MDC **(d)** Reflux **(e)** LiOH, THF:H₂O (2:1) **(f)** HATU, DIPEA, DMF.

CHAPTER 5

Synthesis and Anti-TB Activity Studies of Benzothiazole Guanidinyll Derivatives

Mahesh Bhat^{1,*} and S.L. Belagali²

¹ Department of Chemistry, JSS College for Women, Saraswathipuram, Mysore-09, Karnataka, India

² Environmental Chemistry Laboratory, DOS in Environmental Science, University of Mysore, Mysore-06, Karnataka, India

Abstract: Compounds containing CN₃ group in the open chain or in the ring system are called guanidine and are found in a variety of compounds occurring in natural and synthetic sources. The presence of the guanidine sub unit in the synthesized compound helps to enhance the activity, which helps to interact with the various organisms through the hydrogen bonding. A series of Guanidinyll benzothiazole derivatives were synthesized and evaluated for their anti-mycobacterial activity and cytotoxicity. Anti-mycobacterial study indicates that all the synthesized compounds were appreciably active and many of the compounds have MIC values lower than the standard drugs. The guanidinyll group and electron donating group present in the molecule interacts with the microorganism and arrest the further growth, so synthesized compounds exhibit the excellent activity and some of the compound has MIC at 1.6 µg/mL. In order to rationalize the biological results of the synthesized compounds, molecular docking studies with enoyl acyl carrier reductase (InhA) of *M. tuberculosis* were performed and the synthesized compounds shows the remarkable docking score -5.85 to -9.27, which can be compared with the standard drug Isoniazid (INH) with -6.61 as docking score.

Keywords: Acetone, Activity, Alamar Blue Assay, Ammonium thiocyanate, Anti-TB, Benzothiazole, Benzoyl Chloride, Docking, DprE1, Guanidine, *in-vitro*, *in-silico*, InhA, IC₅₀ value, Mercuric chloride, MIC, Pyrazinamide, Reflux, Triethyl amine, Tuberculosis, Tyrosine.

1. INTRODUCTION

One of the main aims of the synthetic chemistry is the development of new anti-in the market, microorganisms are developing the resistance towards the available

* Corresponding author Mahesh Bhat: JSS College for Women, Saraswathipuram, Mysore-09, India; Tel: +91 9538065170; E-mail: maheshbhat08@gmail.com

drugs and also they have limitations to the new diseases, so, developing new drug molecules plays a major role in defeating the new diseases.

The compounds containing CN_3 group in their open chain or cyclic form are called guanidines and are found in a variety of compounds occurring in natural and synthetic sources [1]. Guanidinyl moieties are basic in nature and have the capacity to form the intermolecular contacts by the hydrogen bonding interactions [2]. The molecules containing guanidinyl groups are much interesting in synthetic chemistry, because nitrogen atoms have lone pairs of electrons and labile -NH hydrogen atom which facilitates to form coordination compounds. Guanidinyl moieties are interacting with the functional groups of enzymes or receptors from the electrostatic interactions by the hydrogen bond [3]. The large number of microbial agents, which originated from the natural and synthetic sources, has guanidinyl functionalities in their structures.




Fig. (1). Highly active guanidine drug molecules.


Guanidine's are physiologically active compounds which exhibit a variety of activities like, antidiabetic, antimicrobial, antiviral, anticancer, antibiotic and anti-inflammatory *etc.* [4 - 6]. The wide range of pharmacological and biological activities made the guanidine as one of the attractive pharmacophores. The presence of the CN_3 group makes the molecules to have efficient affinity towards various substituents, which makes a wide range of biochemical activities of the guanidine compounds. The drugs having less penetration in different membranes

can be enhanced by the introduction of guanidine groups. The guanidinyl moiety was also found in highly active drug molecules, which are shown in Fig. (1).


Similar to thiourea based compounds, there are several compounds incorporated with guanidine subunit, which have been reported to be potent antimicrobial agents. Kamoda *et al.*, (2006), reported the antibacterial activity of mono substituted aryl ester derivatives of guanidine (TG44), an anti-*H. pylori* agent against 54 clinical isolates of *H. pylori* and compared the activity with those of amoxicillin (AMX), clarithromycin (CLR) and metronidazole (MNZ) [7]. TG44 inhibited the growth of *H. pylori* in an MIC range of 0.0625 to 1 µg/mL.

Very less effort has been seen in the synthesis of benzothiazole guanidinyl moiety. Recently benzothiazole guanidines with methoxy substituent and 1- [2-(substituted Benzothiazole) -1, 3-diethyl-4-aryl guanidines (1) have been synthesized and screened for anti-inflammatory and analgesic activities [8, 9].

Katla *et al.*, (2013), synthesized the phosphorylated guanidine derivatives of different heterocyclic moieties and are screened for *in-vitro* and *in-vivo* anti-inflammatory activity. In the series, benzothiazole conjugated moieties (2) showed enhanced activity and had 77% inhibition in membrane stabilization test and 52% inhibition in *in-vivo* methods [10].



(1)



(2)

Siddiqui *et al.*, (2004) synthesized the guanidinyl benzothiazoles and screened for anticonvulsant activity [11]. Anzini *et al.*, (2010) synthesized the guanidinyl derivatives of 6-trifluoro methoxy benzothiazole and they moderately acted as neuroprotective agents, which are applicable to brain diseases [12].

Benzothiazole moiety exhibits a variety of biological activities, so, they can solve the multi drug resistance infectious diseases. The enhancement of the activity of benzothiazole can be achieved by incorporating guanidinyl groups, which initiate the development of novel series of benzothiazole derivatives as shown in Schemes 1 and 2. Here, we synthesized the benzothiazole guanidinyl compounds and screened for anti-TB activity.

Synthesis and Anti-TB Activity Screening of Pyrazole Conjugated Benzothiazole Analogs

Mahesh Bhat^{1,*} and S.L. Belagali²

¹ Department of Chemistry, JSS College for Women, Saraswathipuram, Mysore-09, Karnataka, India

² Environmental Chemistry Laboratory, DOS in Environmental Science, University of Mysore, Mysore-06, Karnataka, India

Abstract: Hybrid derivatives have advantage over the other compounds, because they exhibit the enhanced bioactivity. In this chapter benzothiazole conjugated pyrazole hybrid compounds are taken the study. Pyrazole and benzothiazole scaffolds have their own advantage in the field of medicinal chemistry. In the present study, two series of the pyrazole conjugated benzothiazole derivatives were synthesized by Vilsmeier-Haack reaction, followed by the Schiff's base formation. The newly synthesized compounds were screened for the *in-vitro* and *in-silico* anti-TB activities. They show moderate antibacterial and antioxidant activities. Compounds containing OH, CH₃ and Cl groups exhibit the superior antibacterial activity in the series. Majority of the compounds exhibit the excellent *in-vitro* anti-TB activity, showing the MIC values up to 1.6 µg/mL. Some compounds were show the superior activity compared to the standard (INH and Cfx) and molecular docking studies were also carried out to know the molecular interaction with InhA protein.

Keywords: Acetophenone, Benzothiazole, Conjugation, Cyclization, Docking score, DprE1, Hybrid molecule, Imine, InhA, *In-silico*, *In-vitro*, Isoniazid, Molecular Docking, Phenyl hydrazine, Pyrazofurin, Pyrazole, Schiff's Base, Tuberculosis, Tyrosine, Vilsmeier-Haack.

1. INTRODUCTION

Heterocyclic compound with Nitrogen as a hetero atom represents the highly important class of the moiety in the drug design techniques and are widely used in the synthetic medicinal chemistry, drug discovery, medicines, agro chemistry and many more compounds are in the clinical trials. Ring size and suitable of the Nitrogen hetero atoms are also influences the observed activity. Among the var-

* Corresponding author Mahesh Bhat: Department of Chemistry, JSS College for Women, Saraswathipuram, Mysore-09, Karnataka, India; Tel: +91 9538065170; E-mail: maheshbhat08@gmail.com

ious ring sizes, five memberrings are suitable for drug design, their size, stability and tailoring of the nitrogen, carbon atoms highly influence the activity. Pyrazole is such a heterocyclic moiety and has wide applications in medicines, many of the parent derivatives are used as the drugs and available in the market for treating the various diseases. In pyrazole structure, two adjacent nitrogen atoms are present in the five member ring, and belong to the alkaloid family. Fig. (1) shows the pyrazole based structures, which is used for various treatments. In the structure of Pyrazofuran, pyrazole is linked with the furan moiety, which is a well-known antibiotic drug. The above structure gives the hint towards the hybrid structures and can give the enhanced activity towards the various pharmacological activities. From the various literature, we can observe that, by tailoring the pyrazole moiety with the suitable heterocyclic structure can increases the bioactivity and lowers the toxicity towards the normal cell lines [1, 2]. Benzothiazole is one such moiety, which has sulphur and nitrogen has hetero atom in the five member ring and followed by it is fused with six member aromatic ring and exhibit the various activities [3]. Pyrazole scaffold which is conjugated with other functionality are exhibit a wide spectrum of pharmacological activities *viz*, anti-cancer activity, anti-inflammatory [4], anti-tumor activity [5], anti-TB activity, antihypertensive [5] *etc*. The synthesis of pyrazole derivatives, which is conjugated with benzothiazole has a chance to enhance the biological activities.





Fig. (1). Pyrazole containing molecules in medicine.

If the compound contains the azomethine (-CH=N-) group called imine, which were first synthesized by Hugo Schiff, a German chemist, called them as Schiff's bases [6]. Here, aldehyde or carboxylic acids condense with primary amines, with the elimination of water molecules. Schiff's bases are marked for the various biological activities [7]. The synthetic strategy of the Schiff's bases are applied in the condensation of the aryl/hetero aryl/or alkyl groups with primary amines as the azomethine linkages are wide spread in natural, natural derived or synthesized compounds.

Some of the benzothiazole conjugated heterocyclic compounds through the amide coupling were synthesized by the Bendock *et al.*, (2010), and screened for the antimicrobial activity. From the synthesized compounds, pyrazole amide derivatives of benzothiazole exhibited the excellent gram positive antibacterial activity with IC_{50} value 3.125 $\mu\text{g/mL}$ concentration and moderate activities to other microbial strains [8]. They were also synthesized the Amidino benzothiazole derivatives showed antibacterial activity [9].

Pyrazole conjugated benzothiazole (1) exhibited the anticancer activity against liver and breast carcinoma cell lines [10].



IC_{50} value : 3.125 $\mu\text{g/mL}$ (for *S. aureus* and *S. pyogenes*)

6-Fluoro benzothiazole pyrazole conjugated derivatives were synthesized by benzothiazole hydrazone, followed by the Vilsmeier-Haack cyclization reaction, the resultant compound acted as a good anti-microbial agent. In the series of synthesized compounds, hydroxy substituted derivatives showed the maximum inhibition rate (93%) and the activity decreased with - NO_2 substitution [11].

Pyrazole linked benzothiazoles were synthesized by Abdelgawad *et al.*, (2014) and screened against the cancer cell lines and anti-proliferations were arrested in cell lines of liver cancer (Hep G2) with the IC_{50} value 3.28 μM [12].

Benzothiazole conjugated sulfonamide pyrazole derivatives (2) were screened for the antihelminthic activity for *Perituma posthuma* earth worm and they showed the good activity [13].

SUBJECT INDEX**A**

- Acetaminophen 67
 Acetic acid 93, 94, 95
 glacial 94, 95
 Acetic anhydride 5
 Acetone 77, 80
 Acetophenones 90, 93, 94, 100
 Acid 5, 8, 48, 59, 60, 66, 68, 69, 70, 71, 72
 benzothiazole carboxylic 66
 benzothiazole-2-carboxylic 68, 71
 carboxylic 72
 citric 69
 discovery of para-aminosalicylic 48
 formic 5
 nalidixic 59
 oleic 59, 60
 palmitic 60
 substituted carboxylic 8
 synthesis of benzothiazole-2-carboxylic 71
 trifluoroacetic 70
 trifluoro acetic 66, 68, 72
 Action, bactericidal 48
 Activation 22, 37
 metabolic 22
 Active TB 47
 diseases 47
 Activity 1, 2, 11, 12, 13, 14, 15, 20, 21, 22,
 27, 28, 53, 57, 73, 74, 77, 79, 84, 90, 91,
 92, 93
 analgesic 79
 anti-cancer 1, 28, 91
 anticonvulsant 79
 antihelminthic 92
 anti-inflammatory 27, 79
 anti-mycobacterial 77
 antioxidant 90
 anti-tuberculosis 57, 93
 anti-tubercular 11
 anti-tumor 91
 antmycobacterial 12
 cytotoxicity 27
 myco-bacterial 53
 Adrenaline 20
 Adrenoreceptor agonist 20
 Aided computational techniques 29
 Alamar blue assay 44, 54, 55, 66, 73, 77, 83,
 93, 100, 101
 Algorithms 26, 33, 34
 computational docking 34
 machine learning 26
 program 33
 searching 34
 Alkaline thiocyanate 6
 Amide 8, 14, 27, 66, 67, 70, 72, 105
 bonds, constructing 67
 coupling agent 72
 protected 70
 reflux forms 8
 Amide derivatives 67, 68, 69, 72
 4-nitro phenylalanine 67, 68
 synthesized benzothiazole 69
 Amidino benzothiazole derivatives 92
 Amikacin 49, 51, 61
 Amino benzothiazole carboxylate 70, 71
 Aminoglycosides 47
 Amphotericin 59
 Antibacterial 67, 79, 92
 activity 79
 activities 67, 92
 Anti TB activity 9, 11, 12, 73
 evaluated 11
 against Mtb H37Rv pathogens 12
 of benzothiazole derivatives 9
 Anti-TB 10, 13, 48, 101
 agents 10, 13, 48
 assay 101
 Anti-tubercular 44, 53, 59
 agent 53, 59
 treatment (ATT) 44
 Applications 1, 3, 4, 15, 19, 22, 23, 33, 37, 91
 diversified 3
 of benzothiazole derivatives 4
 of molecular docking 37

open source 23
Approaches 22, 23, 26, 27, 30, 49
 correlated-molecular field 23
 therapeutic 49
 time Hansch-type 22
Arabinogalactan 38, 52, 86, 105
Arabinomannan 52
Aromatic 9, 22, 66, 68, 104
 amines 66, 68
 hydrocarbons 22
 rings 104
Assay 47, 55, 60, 61
 interferon-gamma release 47
Atoms 2, 3, 13, 20, 33, 35, 37, 47, 91
 acceptor 37
 carbon 91
 chloro 13
 donar 37
 methylene carbon 2
 outskirts medicate 47
ATP phosphoribosyl transferase 10
AutoDock 35, 37

B

Benzisothiazole and benzothiazole schiff's bases 10
Benzothiazole 1, 5, 8, 9, 10, 28, 79, 90, 102
 amino 28
 aryl derivatives 8, 9
 carbohydrazide 102
 guanidinyl 79
 scaffolds 1, 90
 schiff's bases 10
 synthesized 1-mercaptop 5
Benzothiazole derivatives 1, 3, 4, 5, 6, 8, 9, 13, 14, 73, 77, 79, 83, 90, 96, 99, 100, 101, 102, 105
 2-amino 6
 6-substituted 83
 conjugated 13, 14, 90, 96, 99, 105
 guanidinyl 14, 77
 synthesized 2-hydrazino 9
Benzothiazole guanidinyl 79

 compounds 79
 moiety 79
Binding 3, 12, 22, 29, 31, 32, 33, 35, 37, 85, 103
 affinity 29
 effect 22
 energies 35
 entropy 35
 interactions 37, 85
 process 35
 superior efficient 103
Biological 19, 20, 21, 22, 23, 24, 26, 31, 34, 37, 60, 78, 79, 83, 91, 92
 activities 19, 20, 21, 22, 23, 26, 31, 34, 78, 79, 83, 91, 92
 decomposition 60
 effects 20, 24
 efficacy, effective 37
 potency 22
 system 21
Blue assay method 83, 93, 101
BOC 68, 70
 group deprotection 70
 protection 68
Brain diseases 79
Brandycardia 20

C

Cancer cell lines 27, 92
Capreomycin 49, 51
Cell wall synthesis inhibitor 49, 50
Chemistry development kit (CDK) 23
Chemo-informatics data management 23
Clarithromycin 79
Column chromatography 81
Comparative molecular field analysis 23
Conformational 32, 66
 changes in ligand and protein 32
 diversity 66
Coupling reagent 66, 68
 acid-amine 68
Crystal structure 33, 35
 ligand-protein complexes 35

Cycloserine 47, 49

D

Decaprenyl 14, 38

phosphoryl- β -D-ribose 14

phosphoryl-D-arabinose 38

phosphoryl-D-ribose 38

Derivatives 1, 10, 12, 13, 14, 20, 23, 28, 53,

74, 79, 90, 95, 97, 100, 101, 102

benzothiazole azetidione 13

benzothiazole carbohydrazide 101

benzothiazole imidino/isoquinazoline 14

benzothiazole isoxazole carboxamide 10

benzothiazole isoxazole 102

hybrid 12, 90

imidazole 53

isopropyl 20

phosphorylated guanidine 79

prop-2-enamido 28

pyrazole aldehyde 95, 97

pyrazole formyl 100

Diethyl 7, 66, 70, 93, 96

carboxylate 96

oxalate 7, 66, 70, 93

Dimensional molecular arrangements 85

Discovery 24, 48

of rifampicin 48

Studio 24

Diseases 9, 19, 46, 67, 79, 91

anti-TB 46

fungal 67

infectious 79

DNA 2, 22, 31, 33, 51, 59

gyrase 51

tests 59

Docking 19, 30, 31, 32, 34, 37

algorithms 32

analysis 34

procedure 32

process 19, 30, 31, 37

software program 32

Docking score 29, 31, 32, 33, 34, 35, 38, 74,

77, 84, 85, 87, 90, 102, 103, 104

generation procedure 32

of benzothiazole guanidinyll derivatives 85

of pyrazole 102

Drug(s) 20, 22, 31, 46, 47, 48, 49, 52, 53, 54,

55, 56, 57, 58, 59, 61, 66, 67, 78

absorption 22

accessible 47

discovery, anti-TB 48

DNA interaction 31

synthetic 48, 66

veterinary 67

Drug Design 33, 90

and dock 33

techniques 90

Drug resistance 46, 79

multi 79

Dubos 44, 56

broth pyrazinamide 44

stock 56

E

Edinburgh method 48

Electrodynamics forces 31

Electron donating groups 14, 74, 77, 84, 87,

102

Electronic structure programs 24

Electrostatic forces 31

Energies 23, 24, 33, 34, 35, 38

empirical scoring function binding 35

flexibility 33

molecular reactivity 23

potential interaction 23

Energy 24, 35

function 35

refinement 24

Enoyl acyl carrier reductase 77, 84

Entropy 31, 32, 35

factors 35

Environmental contaminant 2

Epicenter information arrangement 56

Equilibrium simulations 33

Ethyl 69, 70

acetate layer 69

Benzothiazole-2-carboxylate 70
Ethylene glycol 94

F

FAS-II system 38
Fatty acid biosynthesis pathway 38, 84
Fever 46, 67
First line tuberculosis drugs 49
Flexible 30, 32
 docking 30, 32
 ligand docking model 32
Flow cytometry method 60
Fluorescent derivatives of Mtb 60
Fragment-based methods 34
FT-IR 73, 83, 93
 spectrometric techniques 93
 spectrum 73, 83
Fused heterocyclic compounds 2, 67

G

Genetic algorithms 34, 37
Geometrical matching of ligand and protein 30
Geometry of ligand and protein 29
Guanidine 77, 78, 79, 83, 86
 product 83
 subunits 79, 83
Guanidinyll 78, 79, 88
 functionalities 78
 influence 88
 moieties 78, 79

H

Hammett 22
 relation 22
 relationship 22
Hepatic toxicity 48
Heterocyclic 1, 2, 3, 72, 79, 90, 91, 93
 bioactive 1
 chemistry 93
 compounds 2

 conjugates 72
 moieties 79, 91
 structure 91
High-throughput screening (HTS) 19, 28, 29
Human medicinal services 44
Hydrazine 90, 93, 94, 95, 96, 97, 100, 101
 derivatives 101
 hydrate 94, 96, 97
 phenyl 90, 93, 94, 100
Hydrogen bonding interactions 27, 78
Hydrophobic 20, 105
 center 105
 groups influence 20
Hydrophobicity 33
Hydrophobic moieties 27

I

Imine linkage 93
Immune protection antibodies 66
Immunotherapy 48
Information 19, 21, 23, 24, 25, 26, 28, 36, 37
 stereo-chemical conformational 21
InhA 13, 74, 90, 105
 and DprE1 proteins 13, 74
 proteins 90, 105
Inhibition 9, 10, 11, 12, 37, 50, 51, 60, 79, 105
 of DNA gyrase 51
 of folic acid 50
 of mycolic acid synthesis 51
 tuberculosis 9
Inhibitors 22, 29, 47, 53, 60
 plant growth 22
Injectable second line anti-TB drug 46
In-silico 13, 14, 90
 anti-TB activities 90
 docking study 14
 screening for anti-TB activity 13
Interactions 14, 19, 21, 28, 29, 30, 31, 32, 33,
 34, 35, 37, 38, 78, 85, 86, 87
 effective 32
 electrostatic 29, 31, 35, 78
 hydrophilic 32
 hydrophobic 33, 35

- hydrophobic characteristics 30
- ligand-protein 30
- ligand-receptor 21
- physico-chemical 28
- proffered contacts penalizing repulsive 35
- stacking 14

Interferon-gamma release assay (IGRA) 47

In-vivo treatment 61

Irresistible sicknesses 44

Isoniazid 46, 47, 48, 49, 59, 66, 73, 74, 83, 84, 85, 87, 90, 103

- standard drug 74, 77, 84, 103

Isoprenaline 20

J

Jacobsen cyclization method 8

K

Kanamycin 51

Key enzyme 38, 84

L

Latent TB 47

- diseases 47
- Infection 47

Lawesson's reagent 8, 9

Ligand 14, 19, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38

- binding 33, 34
- bounded 33
- flexible 38
- molecules, targeted 28
- potent 37
- protein 28, 30
- screen 28
- targeted 32

LigPrep 38

- program 38
- software program 38

Lipinsky's rule 36

Liquid simulations 38

Lithium hydroxide monohydrate 71

LogP and biological potency 22

Löwenstein-Jensen 61

- medium 61
- slants 61

LSR-II flow cytometer 60

M

Machine learning method 26

MDR/XDR TB treatment therapy 53

Metabolic enzymes 26

Method for synthesis of benzothiazole 5, 9

- aryl derivatives 9
- scaffold 5

Methyl 6, 13, 20, 74

- isocyanate 6
- substitution 74

Microplate alamar blue assay (MABA) 54, 55

Middlebrook OADC 60

Miliary TB Diseases 47

Minimum 57, 73

- drug concentration 57
- inhibition concentrations for anti-TB activity 73

Modern QSAR practices 21

Molecular 24, 34

- docking process 34
- refractivity parameters 24
- simulation programs 24

Monotherapy 61

Monte Carlo 34, 37

- methods 34
- simulated annealing 37
- simulations 34

MTT 10, 19, 44, 57, 58

- assay 19, 44, 57, 58
- method 10
- reduction 57
- solution 57

Multi-drug resistant (MDR) 14, 46

Mutagenicity 23, 53

Mycobacterial growth inhibition assay (MGIA) 58

- Mycobacterium africanum* 45
Mycobacterium 9, 38, 44, 45, 46, 54, 58, 73, 83, 86, 87, 100, 105
 cell wall 38, 86, 105
 operators 46
 tuberculosis 9, 44, 45, 46, 54, 58, 73, 83, 87, 100
Mycolic acid 38, 51, 53, 105
 biosynthesis 38, 53
 pathway 105
 synthesis 51
- N**
- Neuroprotective agents 79
Nitrate reductase assay/greiss method 58
Nitrogen atoms 15, 27, 78, 90, 91
 adjacent 91
 hetero atoms 15, 27, 90
NMR 83, 93, 100
 and FT-IR spectrometric techniques 93
 and mass spectral data 83
 spectroscopic techniques 100
- O**
- Observed drug susceptibility assay 59
Oxidase 12, 14, 38, 84, 86
 decaprenyl phosphoryl-D-ribose 38, 84
 ribose 86
Oxidative 6, 8
 reagents 8
 ring closure 6
- P**
- Pain, chest 46
Paracetamol 67
Partial least square (PLS) 23
Pesticides 23
Pharmaceutical 2, 20, 37, 46, 67
 companies 46
 drugs 20, 67
 industries 2, 37
Phase 52, 81
 combined organic 81
Phenylalanine 66, 68, 70, 71, 74, 104, 105
 amide derivatives 70, 71
 protected 4-nitro 68
Phenyl isothiocyanate 5
Phosphate-buffered saline (PBS) 60, 61
Polymers 3, 66, 67
 unsaturated elastomeric 3
 urea formaldehyde 67
Potassium
 ferricyanide 8, 9
 thiocyanate 93
Precursor, fatty acid 38
Process, isotope removal 60
Pro drug 53
 compound anti-TB 53
Product 6, 23, 72, 74, 93, 94, 95, 96, 97, 100
 crude 94, 96
 first commercial 23
 purified 74
Properties 20, 22, 23, 24, 28, 33, 36, 66
 biological 20, 23
 donating 66
 molecular 24
 physico-chemical 24, 28
 thermodynamic 33
Protein 4, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 50, 51, 84, 86
 enzyme 37
 misfolded 4
 target 28, 29, 38
 targeted 28
 data bank 36, 38
 preparation wizard 38
 enoyl acyl carrier reductase 38
 synthesis inhibitor 50, 51
Protein-ligand 29, 34, 36
 complexes 36
Protein-ligand docking 29, 37
 programs 37
Protein structures 30, 32, 36, 38
 dimensional 36
Pyrazinamide containing regimens 48
Pyrazole 13, 90, 91, 92, 100, 103, 104, 105

- 5-membered 100
- 6-Fluoro benzothiazole 92
- benzothiazole carbohydrazide 104, 105
- benzothiazole hydrazine 103
- amide derivatives 92
- analog 13
- and benzothiazole scaffolds 90
- moiety 91, 103, 105
- proton 100
- scaffold 91
- structure 91
- Pyrazole conjugated benzothiazole 90, 93, 95, 97
 - analogs 90
 - derivatives 93, 95, 97
- Pyrazole derivatives 91, 92, 93, 95, 97, 100, 102
 - conjugated 100
 - conjugated sulfonamide 92
 - p*-formyl 100
 - synthesis of 91, 95, 97
- PZA 49, 55, 56
 - kit 55
 - supplement 55
- PZase 56
 - exercises 56
 - inhibitory activity assay 56
 - movement test 56

Q

- QSAR 23, 24, 25, 26
 - applicability domain appraisal 23
 - data 25
 - methods 24
 - technique 23
 - tools 25, 26
- QSAR model 19, 22, 23, 24, 25, 26
 - the-3D 23
 - traditional 23
- Quantum theory 23

R

- Radiometric 60
 - assay 60
 - measurement 60
- Reaction, amide coupling 72
- Reactive 22
 - diol-epoxide intermediates 22
- Receptor 1, 14, 19, 27, 28, 29, 30, 32, 33, 36, 37, 78
 - hydrogen 37
 - flexibility 33
- Recrystallization 81, 94, 95, 96, 97
- REMA plate method 13, 56
- Resonance stabilization 88
- Respiratory-related problems 9
- Rifampicin-containing regimens 48
- Rigidification 19, 21
- RNA synthesis Inhibitor 50
- Root mean square deviations (RMSD) 38

S

- SAR 20, 21, 26, 27
 - data 21, 26
 - descriptions 27
 - model 21
 - technique 21
 - tool 20
- Schiff's bases 90, 92, 93, 100
- SDS-DMF solution 57
- Semisynthetic drugs 1
- Software 23, 24, 25, 26, 34, 35, 36
 - computational 34
 - database 24
 - programs 35
 - simulation 34
- Solidified stocks 61
- Solution 24, 56, 57, 58, 59, 60, 61, 69, 70, 73, 80, 81, 93, 94, 95
 - citric acid 69
 - cold 95
 - molecular design 24
 - saline 61

- Solvent 24, 32
 related forces 32
 systems 24
- Somulose 67
- Spectroscopic techniques 12, 73
 protein mass 12
- Stereo-chemical arrangement 20
- Steric 22, 23, 31
 effects 23
 factors 22
 forces 31
- Streptomyces griseus* 48
- Streptomycin 44, 48, 49, 50
- Structural 1, 20, 21, 26, 33
 complexity 33
 diversity 20
 features 26
 refinement 33
 simplification 21
 variations 1
- Structure 2, 19, 20, 21, 22, 23, 24, 29, 32, 33, 36, 37, 38, 49, 91
 based drug design (SBDD) 37
 crystallographic 38
 electronic 22
 hybrid 91
 ligands 32, 36
- Structure activity relationships (SAR) 1, 14, 19, 20, 21, 26, 74, 84, 102
 studies 20, 84, 102
- Substituents 20, 22, 23, 27, 78, 79
 chloro 27
 methoxy 27, 79
- Substitutions 1, 10, 13, 28, 74, 102, 103
 methyl 13
 p-chloro 102
- Sulfide linkage 3
- Sulfur hetero atoms 67
- Surgical devices 28
- Susceptibility 59, 60
 semi-automated radiometric drug 60
- Synthesis 6, 7, 38, 47, 52, 68, 70, 71, 74, 80, 81, 86, 93, 94, 95, 96, 97, 99, 105
 bacterial protein 47
 cell membrane 47
 conjugated benzothiazole derivatives 74
 lipoarabinomannan 38, 86, 105
 macromolecule 47
 mycobacterial cell wall 52
 of 2-aminobenzothiazole 6
 of 2-methyl benzothiazole derivatives 7
 of 2-substituted benzothiazole guanidinyll derivatives 81
 of 6-hydroxy-2-amino benzothiazole 6
 of 6-substituted benzothiazole guanidinyll derivatives 80
 of benzothiazole amide derivatives 68, 71
 of benzothiazole-2-ethyl carboxylate 96
 of benzothiazole guanidinyll derivatives 81
 of benzothiazole-2-hydrazine 94
 of benzothiazole thiourea derivatives 80
 of ethyl benzothiazole-2-carboxylate 70
 of pyrazole conjugated benzothiazole derivatives 93, 95, 96, 97, 99
 represses *Mycobacterium tuberculosis* cell wall 52
- Synthesized urea 11
- T**
- TB 1, 9, 46, 47, 53, 54
 activity 1
 diseases 47, 53, 54
 drugs 47
 elimination 46
 medications 47
 microorganisms 47
 pathogen 9
 treatment 46, 54
- Therapeutic agents 51
- Therapy, combination 48
- Thin layer chromatographic techniques 93
- Topical anesthesia 67
- Toxic hazardsby 23
- Transformation 38, 67
 amide bond 67
 executed 67
- Treatment 4, 8, 20, 34, 35, 46, 47, 48, 49, 53, 54, 61

- ambulatory 49
- computational 34
- streptomycinfor 48
- Triglycerides 67
- Tuberculin skin test (TST) 47
- Tuberculosis 13, 14, 38, 44, 45, 46, 47, 48, 49, 52, 53, 54, 55, 77, 101
 - curing 53
 - first-line active 53
- Tuberculosis activity 1, 15, 58, 83
 - antimycobacterial 15
 - in-vitro* anti-mycobacterial 83
- Tuberculosis 44, 45, 46, 47, 48, 49, 52, 54, 55, 56, 57, 58, 61, 84
 - cells 57
 - chemotherapy centre 49
 - deaths 45
 - diseases 44, 46, 84
 - drugs 47, 48, 49
 - growth 58
 - malady 54
 - strains 56, 57
 - suspension 55
 - treatment 44, 48, 52, 61
- Tyrosine 77, 86, 90, 104

V

- Vilsmeier-Haack 90, 92, 93, 95, 100, 105
 - cyclization reaction 92, 93
 - reaction 90, 100, 105
 - reagent 95, 100
- Virtual computation method 28

W

- Waals force 31, 33
 - of interaction 31
- Waals interactions 35
- Wayne's strategy, adjusted 56
- World health organization 46



Mahesh Bhat

Dr. Mahesh Bhat obtained a Ph.D. from the University of Mysore, Mysore, Karnataka, India. He has 10 years of research experience and 05 years of teaching experience.

He completed a B.Sc. degree from Poorna Prajna College, Udupi, with 86 % marks. During his bachelor's degree, he had received Sir C. V. Raman Scholarship from the Government of Karnataka. He successfully completed his Master's degree in Applied Chemistry from the Department of Chemistry, Mangalore University, Mangalore, Konaje, with distinction, and he was also a recipient of a gold medal for securing the first rank in Applied Chemistry during 2009-2011. He studied Organic, Inorganic, Physical, and Analytical Chemistry and carried out M.Sc. dissertation work at Kores India Limited, Roha, Maharashtra. After completing his Master's degree in 2011, he joined Syngene International Limited (A Biocon Company) and served as a research associate from June 2011 to April 2013. During that period, he had carried out the planning of the reaction schemes, total synthesis, purification, and characterization of the synthesized products.

In 2013, INSPIRE Fellowship (JRF) was awarded to him for the Ph.D. work, and he joined for research under guidance in May-2013. He successfully completed his course work for a Ph.D. degree in Chemistry during the first year. INSPIRE Fellowship (JRF) was upgraded to SRF during March-2016. He cleared the Karnataka State Level Eligibility Test for Lectureship in December 2016 in Chemical Sciences. In January-2018, he was awarded a Ph.D. from the University of Mysore.

Dr. Mahesh Bhat worked on the topic "Synthesis characterization and biological activity studies on Benzothiazole Derivatives." He synthesized many compounds that testify to his potential in the synthetic field. He has good research publications in reputed journals of international acclaim with good impact factors (Around 30 publications). Currently, he is working as an assistant professor in JSS College for Women, Saraswathipuram, Mysuru, since August-2017, where he teaches M.Sc. students of Chemistry.



S.L. Belagali

He obtained a Ph.D. degree from Southampton University, U.K, in 1992 with the research work on natural products synthesis & biological activity evaluation. In 1986, he joined Mangalore University and became the reader in 1995 at the Chemistry department. In October 1999, he joined as a professor & co-coordinator of the Environmental Science department at the Mysore University and also worked as a chairman of the Environmental Science department. He was also a registrar (Administration) at Rani Channamma University, Belagavi, for 15 months. He has guided 20 students for the doctoral degree and four students for the M.Phil degree. On his credential, there are more than 150 publications in national and international reputed journals.